Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
AngioDynamics, Inc. (NASDAQ: ANGO) is a medical technology company whose news flow centers on vascular interventions, oncology technologies, and corporate developments. Company announcements emphasize its focus on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients.
News releases frequently highlight performance across AngioDynamics’ two main platforms, Med Tech and Med Device. Investors can follow updates on Med Tech growth, including results from the Auryon peripheral atherectomy platform, the Mechanical Thrombectomy business (AngioVac and AlphaVac), and the NanoKnife irreversible electroporation platform. Earnings reports describe trends in Med Tech and Med Device net sales, gross margin, and the use of non‑GAAP measures such as adjusted EBITDA and pro forma results.
AngioDynamics also issues news about regulatory milestones and clinical studies. Recent items include FDA IDE approvals for the APEX‑Return study evaluating the AlphaReturn Blood Management System with AlphaVac F1885 in acute pulmonary embolism, and the PAVE clinical study assessing the AngioVac System for right‑sided infective endocarditis. The company has reported FDA 510(k) clearance for a modified AlphaVac F1885 System with expanded indications, as well as publication of the PRESERVE study of the NanoKnife System for prostate tissue ablation in European Urology.
Additional news topics include recognition of the NanoKnife System on TIME’s 2025 Best Inventions list, enrollment milestones in trials such as AMBITION BTK and RECOVER‑AV, participation in investor conferences, and scheduling of quarterly earnings calls. For investors and observers, the ANGO news stream offers insight into product performance, clinical evidence, regulatory progress, and the company’s strategic focus on Med Tech growth.
AngioDynamics (NASDAQ: ANGO) has received CE Mark approval in Europe for its AlphaVac F1885 System. This regulatory milestone allows the company to market the mechanical thrombectomy system for non-surgical removal of thrombi or emboli from the pulmonary arteries, aiding in the treatment of pulmonary embolism (PE). The system aims to improve patient outcomes in the EU, where PE has a higher prevalence compared to the U.S. In December 2023, AngioDynamics completed patient enrollment for its U.S.-based APEX-AV trial, which showed significant decreases in RV/LV ratios and clot burdens, with a low Major Adverse Event rate.
AngioDynamics, Inc. presented results from the APEX-AV trial assessing the AlphaVac F1885 System for pulmonary embolism treatment at SCAI 2024 Scientific Sessions. The trial showed significant improvement in right ventricular function, clot burden reduction, and low Major Adverse Event rate. The FDA clearance of the device marks a milestone in interventional medicine.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.